Table 6.

Hypoglycemic drugs: pooled IPTW-adjusted hazard ratios from subgroup analyses.

Subgroup	N branded	N generics	Mortality HR (95%CI)	p-value for interaction*	MACCE HR (95%CI)	p-value for interaction*
Females	50,026	50,147	1.06 (0.85, 1,31)	0.3072	1.14 (1.03, 1.25)	0.2597
Males	51,019	49,846	1.12 (1.00, 1.25)		1.11 (1.06, 1.16)
Age <= 70 years	63,719	70,352	1.19 (1.11,1.29)	0.0075	1.16 (1.11, 1.22)	0.0008
Age > 70 years	37,326	29,641	1.04 (0.84, 1.29)		1.07 (0.97, 1.18)
No history of CVDD	15,754	21,629	1.06 (0.78, 1.43)	0.5352	1.04 (0.77, 1.40)	0.2720
History of CVDD	85,291	78,364	1.11 (0.96, 1.28)		1.12 (1.06, 1.19)
No diabetes	61,401	78,420	1.14 (1.00, 1.30)	0.0475	1.15 (1.11, 1.19)	0.0027
Oral DM therapy but no insulin use	36,445	19,061	1.07 (0.93, 1.23)		1.09 (1.02, 1.16)
Insulin use	3,199	2,512	0.97 (0.69, 1.38)		1.09 (0.84, 1.40)
Time-dependent effect: <= 6 months	101,045	99,993	1.16 (1.06, 1.26)	0.0269	1.08 (1.02, 1.15)	0.3153
> 6 months	85,409	84,899	1.03 (0.82, 1.29)		1.11 (1.00, 1.24)

*p-value for interaction of a variable with treatment, i.e., for testing the null hypothesis that HR is equal in the subgroups.